Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study
Standard
Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study. / Gliem, Martin; Birtel, Johannes; Herrmann, Philipp; Fimmers, Rolf; Berger, Moritz; Coch, Christoph; Wingen, Almut; Holz, Frank G; Charbel Issa, Peter.
In: GRAEF ARCH CLIN EXP, Vol. 258, No. 2, 02.2020, p. 311-318.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study
AU - Gliem, Martin
AU - Birtel, Johannes
AU - Herrmann, Philipp
AU - Fimmers, Rolf
AU - Berger, Moritz
AU - Coch, Christoph
AU - Wingen, Almut
AU - Holz, Frank G
AU - Charbel Issa, Peter
PY - 2020/2
Y1 - 2020/2
N2 - PURPOSE: To evaluate the use of 2 mg intravitreal aflibercept for treatment of choroidal neovascularization (CNV) secondary to angioid streaks in patients with pseudoxanthoma elasticum (PXE).METHODS: In this 12-month prospective, open-label, uncontrolled, non-randomized interventional clinical trial, 15 PXE patients with CNV (mean age: 53 years, range 22-65) received one initial intravitreal injection of 2 mg aflibercept. Further injections were based on CNV activity at monthly examinations. The primary endpoint was change of best corrected visual acuity (BCVA) after 12 months. Secondary outcomes were change of central retinal thickness (CRT), leakage from CNV, retinal sensitivity, and vision-related quality of life.RESULTS: BCVA improved from 75.0 ± 10.8 (± SD, Snellen equivalent 20/32) to 79.3 ± 7.3 ETDRS letters (20/32) at final visit (p = 0.083). CRT decreased from 317 ± 81 to 279 ± 51 μm (p = 0.004). Retinal sensitivity on microperimetry changed from 17.8 ± 4.5 to 18.5 ± 4.3 dB (p = 0.103) and vision-related quality of life from a VQF-25 score of 80.7 ± 10.4 to 83.5 ± 14.5 (p = 0.554). The mean number of injections was 6.7 ± 2.6, and 5 participants had persistent or reactivated CNV activity at final visit. The observed adverse events were comparable with studies on aflibercept for other indications.CONCLUSION: The results of this study indicate that intravitreal aflibercept is a treatment option for CNV secondary to PXE.
AB - PURPOSE: To evaluate the use of 2 mg intravitreal aflibercept for treatment of choroidal neovascularization (CNV) secondary to angioid streaks in patients with pseudoxanthoma elasticum (PXE).METHODS: In this 12-month prospective, open-label, uncontrolled, non-randomized interventional clinical trial, 15 PXE patients with CNV (mean age: 53 years, range 22-65) received one initial intravitreal injection of 2 mg aflibercept. Further injections were based on CNV activity at monthly examinations. The primary endpoint was change of best corrected visual acuity (BCVA) after 12 months. Secondary outcomes were change of central retinal thickness (CRT), leakage from CNV, retinal sensitivity, and vision-related quality of life.RESULTS: BCVA improved from 75.0 ± 10.8 (± SD, Snellen equivalent 20/32) to 79.3 ± 7.3 ETDRS letters (20/32) at final visit (p = 0.083). CRT decreased from 317 ± 81 to 279 ± 51 μm (p = 0.004). Retinal sensitivity on microperimetry changed from 17.8 ± 4.5 to 18.5 ± 4.3 dB (p = 0.103) and vision-related quality of life from a VQF-25 score of 80.7 ± 10.4 to 83.5 ± 14.5 (p = 0.554). The mean number of injections was 6.7 ± 2.6, and 5 participants had persistent or reactivated CNV activity at final visit. The observed adverse events were comparable with studies on aflibercept for other indications.CONCLUSION: The results of this study indicate that intravitreal aflibercept is a treatment option for CNV secondary to PXE.
KW - Adult
KW - Choroid/pathology
KW - Choroidal Neovascularization/diagnosis
KW - Female
KW - Fluorescein Angiography
KW - Follow-Up Studies
KW - Fundus Oculi
KW - Humans
KW - Intravitreal Injections
KW - Male
KW - Middle Aged
KW - Prospective Studies
KW - Pseudoxanthoma Elasticum/complications
KW - Quality of Life
KW - Receptors, Vascular Endothelial Growth Factor/administration & dosage
KW - Recombinant Fusion Proteins/administration & dosage
KW - Tomography, Optical Coherence
KW - Treatment Outcome
KW - Visual Acuity
KW - Young Adult
U2 - 10.1007/s00417-019-04551-4
DO - 10.1007/s00417-019-04551-4
M3 - SCORING: Journal article
C2 - 31863395
VL - 258
SP - 311
EP - 318
JO - GRAEF ARCH CLIN EXP
JF - GRAEF ARCH CLIN EXP
SN - 0721-832X
IS - 2
ER -